DATA GRAPHICS | Data Byte
Biogen’s Spinraza continues quarter over quarter fall in SMA sales
Roche’s Evrysdi, Novartis’ Zolgensma continue 2021 growth
February 7, 2022 10:14 PM UTC
Sales of Biogen’s SMA therapy Spinraza continued to decline as both of its competitors saw strong numbers in 2021.
Biogen Inc. (NASDAQ:BIIB) reported its third straight quarter of falling sales for Spinraza nusinersen as oral small molecule competitor Evrysdi risdiplam from PTC Therapeutics Inc. (NASDAQ:PTCT) and Roche (SIX:ROG; OTCQX:RHHBY) ate into its market share. Roche reported 2021 sales of CHF602 million ($658.2 million), an increase of 945% from 2020 when the therapy was launched...